

INCYTE CORP  
Form 8-K  
September 08, 2003

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report: September 8, 2003

(Date of earliest event reported)

---

## INCYTE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	0-27488	94-3136539
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
3160 Porter Drive, Palo Alto, California		94304
(Address of principal executive offices)		(Zip Code)

**Registrant's telephone number, including area code: (650) 855-0555**

---

Item 5. Other Events.

On September 8, 2003, Incyte Corporation ( Incyte ) announced that it had entered into a collaborative licensing agreement with Pharmasset, Ltd. ( Pharmasset ) to develop and commercialize the antiretroviral drug Reversatso known as RVT, D-D4FC or DPC-817, which is currently in Phase IIa clinical development for the treatment of human immunodeficiency virus (HIV) infections under an approved US FDA Investigational New Drug (IND) application. Incyte will pay Pharmasset an upfront payment as well as performance milestone payments and future royalties on net sales in exchange for exclusive rights in the U.S., Europe and certain other markets to develop, manufacture and market the drug. Pharmasset will retain marketing and commercialization rights in certain territories, including South America, Mexico, Africa, the Middle East, Korea and China.

A joint press release was issued by Incyte and Pharmasset on September 8, 2003, announcing the collaborative licensing agreement. The joint press release is attached as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press release issued by Incyte Corporation and Pharmasset, Ltd. dated September 8, 2003

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 8, 2003.

INCYTE CORPORATION

By: \_\_\_\_\_ /s/ LEE BENDKGEY

Lee Bendkgey  
Executive Vice President and  
General Counsel

**INDEX TO EXHIBITS**

**Exhibit  
Number**

---

**Description**

---

99.1

Press release issued by Incyte Corporation and Pharmasset, Ltd. dated September 8, 2003